Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 8, 2022.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
In the AAN 2022 presidential plenary session, a trio of neurologists discussed a variety of issues stemming from the COVID-19 pandemic and how they impacted research efforts in neurological diseases.
The pediatric epileptologist at Cleveland Clinic’s Epilepsy Center discussed data presented at AAN 2022 on the use of ganaxolone in CDD, as well as how its recent approval sets the stage for the future.
In an AAN 2022 Hot Topics plenary session, Miranda E. Orr, PhD, highlighted the potential of targeting senescent cells with senolytics as a therapeutic approach to age-related diseases such as Alzheimer disease, and detailed the ongoing phase 2 SToMP-AD clinical trial (NCT04685590).
At AAN 2022, the medical director and chief medical officer of the New England Center for Neurology and Headache spoke about the phase 2 STEMTRA trial results of the stem cell treatment SB623.
As part of a new NeurologyLive® Roundtable discussion, Thomas Jefferson University neurosurgery experts Chengyuan Wu, MD, MSBmE, and Ashwini Sharan, MD, discuss the state-of-the-art treatment for patients with neurological diseases affecting the brain and spine.